Gil D Rabinovici

List of Publications by Year
in descending order

220 papers	25,294 citations	12330 69 h-index	7950 149 g-index
228 all docs	228 docs citations	228 times ranked	18099 citing authors

#	Article	IF	Citations
1	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
3	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
5	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	8.1	899
6	Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain, 2010, 133, 1352-1367.	7.6	876
7	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 2016, 139, 1551-1567.	7.6	833
8	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
9	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain, 2017, 140, 3286-3300.	7.6	472
10	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	30.7	471
11	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
12	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
13	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
14	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 1286.	7.4	391
15	Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nature Medicine, 2021, 27, 871-881.	30.7	354
16	Frontotemporal Lobar Degeneration. CNS Drugs, 2010, 24, 375-398.	5.9	353
17	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	12.4	353
18	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	4.2	341

#	ARTICLE	IF	CITATIONS
19	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	7.6	319
20	Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging. Cerebral Cortex, 2011, 21, 2399-2407.	2.9	306
21	Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
22	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain, 2013, 136, 844-858.	7.6	280
23	Association of Lifetime Cognitive Engagement and Low β-Amyloid Deposition. Archives of Neurology, 2012, 69, 623.	4.5	278
24	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
25	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	7.6	226
26	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	10.2	220
27	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
28	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	10.2	214
29	Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	10.3	202
30	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. Journal of Neuroscience, 2018, 38, 530-543.	3.6	201
31	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	5.3	198
32	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	3.6	196
33	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	3.9	179
34	Multisite study of the relationships between antemortem [11C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
35	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurology, 2016, 73, 691.	9.0	151
36	18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	5.3	148

#	Article	IF	Citations
37	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
38	Plasma biomarkers of astrocytic and neuronal dysfunction in early‐and late‐onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.8	143
39	Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurology, 2013, 70, 1512-9.	9.0	139
40	Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage, 2012, 59, 1152-1160.	4.2	137
41	Timing and significance of pathological features in *C9orf72* expansion-associated frontotemporal dementia. Brain, 2016, 139, 3202-3216.	7.6	136
42	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
43	Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
44	Alzheimer's pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	7.6	131
45	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	2.7	126
46	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
47	18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research and Therapy, 2019, 11, 13.	6.2	121
48	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
49	Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurology, 2016, 73, 1078.	9.0	115
50	Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
51	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	8.4	111
52	Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia. Brain, 2016, 139, 2778-2791.	7.6	108
53	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	1.9	107
54	Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11606-11611.	7.1	105

#	ARTICLE	IF	CITATIONS
55	Divergent CSF Â alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 244-250.	1.9	101
56	Controversy and Progress in Alzheimer's Disease â€" FDA Approval of Aducanumab. New England Journal of Medicine, 2021, 385, 771-774.	27.0	101
57	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. Acta Neuropathologica, 2019, 137, 209-226.	7.7	100
58	18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	7.6	100
59	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain, 2021, 144, 2186-2198.	7.6	100
60	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
61	Reference Tissueâ€"Based Kinetic Evaluation of ^{18}F-AV-1451 for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 332-338.	5.0	94
62	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	3.7	94
63	Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of *APOB*. JAMA Neurology, 2019, 76, 809.	9.0	94
64	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
65	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
66	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ^{18}F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	9.0	85
67	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84
68	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	9.0	81
69	Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathologica, 2018, 135, 85-93.	7.7	80
70	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
71	Frontotemporal dementia with the V337M *MAPT* mutation. Neurology, 2017, 88, 758-766.	1.1	76
72	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurology, 2018, 75, 342.	9.0	76

#	ARTICLE	IF	CITATIONS
73	Dynamic relationships between age, amyloid-Î² deposition, and glucose metabolism link to the regional vulnerability to Alzheimerâ€™s disease. Brain, 2016, 139, 2275-2289.	7.6	75
74	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.1	75
75	Alzheimerâ€™s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathologica, 2019, 138, 597-612.	7.7	75
76	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology, 2016, 86, 600-610.	1.1	73
77	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	2.7	73
78	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
79	Association of <i>APOE4</i> and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.1	73
80	Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants. Neurobiology of Aging, 2015, 36, 2678-2686.	3.1	72
81	Late-onset Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 14-33.	0.8	70
82	Cavum Septum Pellucidum in Retired American Pro-Football Players. Journal of Neurotrauma, 2016, 33, 157-161.	3.4	68
83	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.1	65
84	Regional AÎ²-tau interactions promote onset and acceleration of Alzheimerâ€™s disease tau spreading. Neuron, 2022, 110, 1932-1943.e5.	8.1	64
85	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. Brain, 2019, 142, 460-470.	7.6	63
86	Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California. JAMA Neurology, 2021, 78, 657.	9.0	62
87	Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathologica, 2010, 119, 365-374.	7.7	59
88	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage: Clinical, 2014, 4, 508-516.	2.7	59
89	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.8	59
90	Neurophysiological signatures in Alzheimerâ€™s disease are distinctly associated with TAU, amyloid-Î² accumulation, and cognitive decline. Science Translational Medicine, 2020, 12, .	12.4	59

#	ARTICLE	IF	CITATIONS
91	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
92	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	7.6	58
93	Associations Between Tau, Î²-Amyloid, and Cognition in Parkinson Disease. JAMA Neurology, 2018, 75, 227.	9.0	57
94	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. Human Brain Mapping, 2016, 37, 4234-4247.	3.6	55
95	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	9.0	54
96	MCPâ€‘1 and eotaxinâ€‘1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 91-97.	2.4	53
97	Visuospatial Functioning in the Primary Progressive Aphasias. Journal of the International Neuropsychological Society, 2018, 24, 259-268.	1.8	53
98	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	2.7	53
99	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	2.7	50
100	Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. American Journal of Human Genetics, 2020, 106, 632-645.	6.2	50
101	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	3.1	49
102	Amyloid imaging, risk disclosure and Alzheimerâ€™s disease: ethical and practical issues. Neurodegenerative Disease Management, 2013, 3, 219-229.	2.2	48
103	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 266-273.	1.9	47
104	Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy. JAMA Neurology, 2018, 75, 728.	9.0	46
105	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimerâ€™s disease. ELife, 0, 11, .	6.0	45
106	Research Criteria for the Behavioral Variant of Alzheimer Disease. JAMA Neurology, 2022, 79, 48.	9.0	44
107	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Network Open, 2022, 5, e228392.	5.9	44
108	Sleep changes without medial temporal lobe or brain cortical changes in communityâ€‘dwelling individuals with subjective cognitive decline. Alzheimer's and Dementia, 2017, 13, 783-791.	0.8	43

#	Article	IF	Citations
109	Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. JAMA Neurology, 2020, 77, 517.	9.0	43
110	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	2.6	43
111	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Brain, 2022, 145, 713-728.	7.6	43
112	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
113	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex, 2018, 108, 252-264.	2.4	41
114	Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12101.	2.4	41
115	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	6.4	41
116	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	2.5	40
117	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.1	39
118	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology, 2018, 90, e1047-e1056.	1.1	36
119	Diagnostic Accuracy of Amyloid versus ^{18}F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. Annals of Neurology, 2021, 89, 389-401.	5.3	34
120	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	2.9	34
121	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
122	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.8	34
123	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. Journal of Nuclear Medicine, 2022, 63, 13S-19S.	5.0	34
124	Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia. Brain, 2022, 145, 4080-4096.	7.6	34
125	Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 358-367.	2.4	33
126	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease. JAMA Neurology, 2021, 78, 445.	9.0	33

#	ARTICLE	IF	CITATIONS
127	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research and Therapy, 2015, 7, 8.	6.2	32
128	The Rise of Pseudomedicine for Dementia and Brain Health. JAMA - Journal of the American Medical Association, 2019, 321, 543.	7.4	31
129	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. Journal of Alzheimer's Disease, 2016, 51, 339-343.	2.6	30
130	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	6.4	30
131	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 15-22.	2.4	29
132	Metabolic brain networks in aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 987-999.	2.7	29
133	Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiology of Aging, 2021, 105, 86-98.	3.1	29
134	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. Canadian Journal of Neurological Sciences, 2016, 43, 503-512.	0.5	27
135	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
136	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. Journal of Neurotrauma, 2018, 35, 2015-2024.	3.4	25
137	Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer's disease. Brain, 2022, 145, 744-753.	7.6	25
138	Evaluating and treating neurobehavioral symptoms in professional American football players. Neurology: Clinical Practice, 2015, 5, 285-295.	1.6	24
139	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
140	Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Brain, 2022, 145, 4489-4505.	7.6	23
141	Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?. NeuroImage: Clinical, 2019, 21, 101628.	2.7	22
142	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	6.4	22
143	Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review. Acta Neuropathologica Communications, 2021, 9, 96.	5.2	22
144	Validation of online functional measures in cognitively impaired older adults. Alzheimer's and Dementia, 2020, 16, 1426-1437.	0.8	20

#	Article	IF	Citations
145	Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases. JAMA Neurology, 2022, 79, 498.	9.0	20
146	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	6.4	18
147	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
148	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research and Therapy, 2020, 12, 148.	6.2	17
149	Evaluation of a visual interpretation method for tau–PET with [18] F–flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	2.4	17
150	Reduced synchrony in alpha oscillations during life predicts *post mortem* neurofibrillary tangle density in early–onset and atypical Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 2009-2019.	0.8	17
151	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	1.9	17
152	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage, 2022, 246, 118775.	4.2	17
153	Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease. JAMA Neurology, 2021, 78, 143.	9.0	16
154	Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET. Journal of Nuclear Medicine, 2021, 62, 612-613.	5.0	16
155	The severity of neuropsychiatric symptoms is higher in early–onset than late–onset Alzheimer's disease. European Journal of Neurology, 2022, 29, 957-967.	3.3	16
156	Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series. Journal of Neurotrauma, 2022, 39, 1195-1213.	3.4	16
157	Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3302-3313.	4.3	15
158	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease, 2018, 65, 1029-1039.	2.6	14
159	Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. JAMA Neurology, 2020, 77, 358.	9.0	14
160	Seizures in corticobasal degeneration: A case report. Neurocase, 2009, 15, 352-356.	0.6	12
161	Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase, 2016, 22, 76-83.	0.6	12
162	BHA–CS: A novel cognitive composite for Alzheimer's disease and related disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12042.	2.4	12

#	ARTICLE	IF	CITATIONS
163	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
164	Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia. Brain Communications, 2019, 1, fcz027.	3.3	11
165	[DT–01–01]: IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY. Alzheimer's and Dementia, 2017, 13, P1474.	0.8	10
166	Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants. Alzheimer's and Dementia, 2020, 16, 1704-1713.	0.8	10
167	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET. Alzheimer's Research and Therapy, 2021, 13, 36.	6.2	10
168	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	6.4	10
169	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.1	10
170	The Translational Journey of Brain β-Amyloid Imaging. JAMA Neurology, 2015, 72, 265.	9.0	9
171	Advances and Gaps in Understanding Chronic Traumatic Encephalopathy. JAMA - Journal of the American Medical Association, 2017, 318, 338.	7.4	9
172	Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior, 2021, 15, 2417-2425.	2.1	9
173	Crossed cerebellar diaschisis on ^{18}F-FDG PET: Frequency across neurodegenerative syndromes and association with ^{11}C-PIB and ^{18}F-Flortaucipir. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2329-2343.	4.3	9
174	Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia. Neurocase, 2019, 25, 39-47.	0.6	8
175	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. Seminars in Neurology, 2020, 40, 394-410.	1.4	7
176	The Rapid Naming Test: Development and initial validation in typically aging adults. Clinical Neuropsychologist, 2022, 36, 1822-1843.	2.3	7
177	Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. Journal of Nuclear Medicine, 2022, 63, 830-832.	5.0	7
178	Corticobasal syndrome: overcoming the artificial divide between disorders of cognition and movement. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 404-404.	1.9	5
179	Amyloid biomarkers: pushing the limits of early detection. Brain, 2016, 139, 1008-1010.	7.6	5
180	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. Alzheimer Disease and Associated Disorders, 2018, 32, 35-42.	1.3	5

#	ARTICLE	IF	CITATIONS
181	Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. Journal of Alzheimer's Disease, 2018, 63, 1025-1033.	2.6	5
182	Spatiotemporal imaging phenotypes of tau pathology in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045612.	0.8	5
183	Professional Soccer and Dementia Risk—The Ugly Side of the Beautiful Game. JAMA Neurology, 2021, 78, 1049.	9.0	5
184	IC-P-161: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P107-P109.		4
185	FTS—04—02: Imaging dementia: Evidence for amyloid scanning (IDEAS)—a national study to evaluate the clinical utility of amyloid PET. Alzheimer's and Dementia, 2015, 11, P263.	0.8	4
186	Rare <i>APOE</i> Missense Variants—Can We Overcome <i>APOE</i> ε4 and Alzheimer Disease Risk?. JAMA Neurology, 2022, 79, 649.	9.0	4
187	Imaging prodromal FTD. Neurology, 2013, 81, 1282-1283.	1.1	3
188	Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?. Neurocase, 2016, 22, 161-167.	0.6	3
189	Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease. JAMA Internal Medicine, 2019, 179, 1736.	5.1	3
190	Dominantly inherited Alzheimer's disease: a compass for drug development. Nature Medicine, 2021, 27, 1148-1150.	30.7	3
191	Amyloid imaging in atypical dementia. Cmaj, 2014, 186, 695-695.	2.0	2
192	Focal cerebral β-amyloid angiopathy. Neurology: Clinical Practice, 2017, 7, 444-448.	1.6	2
193	Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase, 2018, 24, 1-6.	0.6	2
194	Predicting amyloid status using self-report information from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12102.	2.4	2
195	Amyloid and tau PET in sporadic early-onset Alzheimer's disease: Preliminary results from LEADS. Alzheimer's and Dementia, 2020, 16, e041613.	0.8	2
196	IC—P—012: PREDICTORS OF β—AMYLOID POSITIVITY IN COGNITIVELY IMPAIRED PATIENTS: DATA FROM THE IMAGING DEMENTIA €" EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY. Alzheimer's and Dementia, 2019, 15, P21.	0.8	1
197	Glucose metabolism mainly reflects local atrophy and tau pathology at symptomatic stages of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043968.	0.8	1
198	Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044830.	0.8	1

#	Article	IF	Citations
199	Predicting amyloid status using remote online selfâ€report and cognitive assessment: The Brain Health Registry. Alzheimer's and Dementia, 2020, 16, e045932.	0.8	1
200	Colocalization of atrophy and tau improves AI classification of Alzheimer phenotypical variants. Alzheimer's and Dementia, 2020, 16, e046258.	0.8	1
201	Legal and Policy Challenges to Addressing Cognitive Impairment in Federal Officials. JAMA Neurology, 2019, 76, 392.	9.0	1
202	IC-P-023: AMYLOID PET HAS GREATER CLINICAL IMPACT THAN FDG PET IN THE DIFFERENTIAL DIAGNOSIS OF AD AND FTD. , 2014, 10, P17-P18.		0
203	O4-01-03: AMYLOID PET HAS GREATER CLINICAL IMPACT THAN FDG PET IN THE DIFFERENTIAL DIAGNOSIS OF AD AND FTD. , 2014, 10, P249-P249.		0
204	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0
205	P1â€253: Diagnostic Accuracy of Amyloidâ€Versus Fdgâ€Pet in Autopsyâ€Confirmed Dementia. Alzheimer's and Dementia, 2016, 12, P506.	0.8	0
206	[S1â€"01â€"01]: AMYLOID AND TAU DEPOSITION ACROSS AGES. Alzheimer's and Dementia, 2017, 13, P170.	0.8	0
207	O3â€13â€01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.8	0
208	PL-05-01: PATHOGENESIS OF ALZHEIMER'S DISEASE: WHAT HAVE WE LEARNED FROM NEUROIMAGING?. , 2018, 14, P1635-P1635.		0
209	P1â€597: AMYLOID NEUROIMAGING AND GENETICS INITIATIVE: IMPLEMENTING DNA COLLECTION USING NOVEL CONSENTING APPROACHES FOR AN IDEAS ADDâ€ON STUDY. Alzheimer's and Dementia, 2018, 14, P566.	0.8	0
210	ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.8	0
211	O1â€01â€05: DISTINCT NEURAL OSCILLATION ABNORMALITIES ASSOCIATED WITH AMYLOIDâ€BETA AND TAU IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P213.	0.8	0
212	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.8	0
213	Comparison of 18 Fâ€Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining Tâ€status in the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e037276.	0.8	0
214	Impact of cortical and subcortical atrophy in the diagnosis and prognosis of bvFTD: A multicenter longitudinal study. Alzheimer's and Dementia, 2020, 16, e044984.	0.8	0
215	Comparative diagnostic performance of plasma Pâ€tau217 and Pâ€tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipirâ€PET uptake. Alzheimer's and Dementia, 2020, 16, e045755.	0.8	0
216	Longitudinal Earlyâ€onset Alzheimerâ€™s Disease Study (LEADS) genetic screening: Initial results. Alzheimer's and Dementia, 2021, 17, e056493.	0.8	0

#	Article	IF	Citations
217	Inâ€depth investigation in tau positron emission tomography tracers offâ€target binding with voxelâ€toâ€voxel correlation analysis of tau and amyloid PET signal to histological iron and tau deposit in nonâ€Alzheimer tauopathies. Alzheimer's and Dementia, 2021, 17, .	0.8	0
218	Diagnostic applications of tau PET. Alzheimer's and Dementia, 2021, 17, .	0.8	0
219	White matter hyperintensities and regional tauâ€PET signal independently contribute to cognitive deficits in symptomatic patients on the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
220	Headâ€toâ€head comparison of [¹⁸ F]Flortaucipir and amyloid PET visual reads for differential diagnosis: An international, multiâ€center study. Alzheimer's and Dementia, 2021, 17, .	0.8	0